Search

Matthew Mcleay Phones & Addresses

  • Roeland Park, KS
  • Columbia, MO
  • Omaha, NE
  • Lake Ozark, MO
  • Maryville, MO

Work

Company: Midwest Pulmonary/Critical Care, P.C. Address: 8552 Cass St Suite 301, Omaha, NE 68114

Education

School / High School: Univ Of Ne Coll Of Med 1988

Ranks

Certificate: American Board of Internal Medicine Certification in Internal Medicine

Images

Professional Records

Medicine Doctors

Matthew Mcleay Photo 1

Dr. Matthew T Mcleay - MD (Doctor of Medicine)

View page
Hospitals:
Midwest Pulmonary/Critical Care, P.C.
8552 Cass St Suite 301, Omaha, NE 68114

Memorial Community Hospital OP Clinic
810 N 22Nd St, Blair, NE 68008

Midwest Sleep Center
8552 Cass St Suite 201, Omaha, NE 68114

Alegent Creighton Health Bergan Mercy Medical Center
7500 Mercy Road, Omaha, NE 68124

Alegent Creighton Health Lakeside Hospital
16901 Lakeside Hills Court, Omaha, NE 68130

The Nebraska Methodist Hospital
8303 Dodge Street, Omaha, NE 68114
Education:
Medical Schools
Univ Of Ne Coll Of Med
Graduated: 1988
Matthew Mcleay Photo 2

Matthew T. Mcleay

View page
Specialties:
Pulmonary Disease, Sleep Medicine
Work:
Midwest PulmonaryMidwest Pulmonary Critical Care
8019 Cass St, Omaha, NE 68114
(402) 390-0606 (phone), (402) 390-0899 (fax)
Education:
Medical School
University of Nebraska College of Medicine
Graduated: 1988
Procedures:
Pulmonary Function Tests
Conditions:
Obstructive Sleep Apnea
Pulmonary Embolism
Acute Bronchitis
Acute Sinusitis
Bronchial Asthma
Languages:
English
Description:
Dr. McLeay graduated from the University of Nebraska College of Medicine in 1988. He works in Omaha, NE and specializes in Pulmonary Disease and Sleep Medicine. Dr. McLeay is affiliated with Nebraska Methodist Hospital.
Matthew Mcleay Photo 3

Matthew Thomas McLeay, Omaha NE

View page
Specialties:
Internal Medicine
Critical Care Medicine
Pulmonary Disease
Critical Care Medicine
Work:
Midwest Pulmonary / Critical Care
8552 Cass St, Omaha, NE 68114
Midwest Pulmonary Crtcl Care
8552 Cass St, Omaha, NE 68114
Midwest Pulmonary Crtcl Care
7831 Chicago Ct, Omaha, NE 68114
Midwest Pulmonary/Critical Care, P.C.
810 N 22Nd St, Blair, NE 68008
Mp/Cc PC
6901 N 72Nd St, Omaha, NE 68122
Education:
University of Nebraska (1988)
Matthew Mcleay Photo 4

Matthew Thomas McLeay, Omaha NE

View page
Specialties:
Pulmonologist
Address:
8552 Cass St, Omaha, NE 68114
Education:
University of Nebraska, College of Medicine - Doctor of Medicine
Parkland Memorial Hospital - Fellowship - Pulmonary Disease and Critical Care Medicine (Internal Medicine)
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Critical Care Medicine (Internal Medicine)
American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Matthew T. Mcleay
Principal
8552 Cass LLC
Medical Doctor's Office · Nonclassifiable Establishments
8552 Cass St, Omaha, NE 68114
Matthew T. Mcleay
Principal
Rustad Dermatology
Medical Doctor's Office · Offices and Clinics of Medical Doctors, Nsk · Dermatologist · Laser Skin Treatment · Pediatric Dermatologist
8552 Cass St, Omaha, NE 68114
(402) 391-7546
Matthew T. Mcleay
Medical Doctor, President, Principal
Mp Cc PC
Health Practitioner's Office
8552 Cass St, Omaha, NE 68114
Matthew T. Mcleay
Pulmonary Diseases
Matthew T McLeary
Medical Doctor's Office
8552 Cane St, Omaha, NE 68114
(402) 390-0606
Matthew Thomas Mcleay
Matthew McLeay MD
Internist
7831 Chicago Ct, Omaha, NE 68114
(402) 390-0606
Matthew T. Mcleay
Medical Doctor
Midamerica Cardiovascular Inst
Health/Allied Services
8552 Cass St, Omaha, NE 68114
(402) 551-0351

Publications

Us Patents

Anti-Fibroblastic Fluorochemical Emulsion Therapies

View page
US Patent:
20120076777, Mar 29, 2012
Filed:
Jul 1, 2011
Appl. No.:
13/175305
Inventors:
Matthew T. McLeay - Omaha NE, US
Assignee:
MTM Research LLC - Omaha NE
International Classification:
A61K 31/02
C12N 5/071
A61P 35/00
A61K 31/7068
A61K 39/395
US Classification:
4241331, 514759, 514 49, 435375
Abstract:
The present invention is directed to compositions and methods targeting tissue resident cells, such as fibroblasts, in a subject harboring conditions or at risk for conditions that would benefit from anti-fibroblastic therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent delivered in combination with the fluorochemical composition.

Megaribavirin Alone Or Combination Of Other Antiviral, Antioxidant And A Perflubron Emulsion For Treatment Of Viral Disease

View page
US Patent:
20100297033, Nov 25, 2010
Filed:
May 21, 2009
Appl. No.:
12/454663
Inventors:
Matthew T. McLeay - Omaha NE, US
International Classification:
A61K 9/12
A61K 31/708
A61K 38/44
US Classification:
424 45, 514 43, 424 944
Abstract:
The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains “swine” 2009 H1N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg/ml) alone or combined with or without other antivirals, a perfluorocarbon emulsion and anti-inflammatory/anti-oxidants. Where applicable, the perfluorocarbon emulsion may dissolve these agents enabling a depot effect and possible protracted delivery. In addition perfluorocarbon emulsions have the possible added benefit of oxygen carrying capacity and alveolar nitric oxide sequestration, which may reduce peroxynitrite formation and decrease Influenza severity.

Fluorochemical Targeted Therapies

View page
US Patent:
20220175972, Jun 9, 2022
Filed:
Feb 25, 2022
Appl. No.:
17/681596
Inventors:
- San Diego CA, US
Matthew T. McLeay - Omaha NE, US
International Classification:
A61K 49/00
A61K 31/02
A61K 41/00
C07K 16/28
A61P 35/00
A61K 31/7004
A61K 33/00
A61K 38/39
A61K 31/135
A61K 31/4045
A61K 45/06
A61K 31/695
A61K 31/08
A61P 35/04
A61K 31/496
A61K 31/517
A61K 31/7068
A61K 38/06
A61K 39/395
A61K 47/24
A61K 51/02
A61N 5/06
Abstract:
The present invention is directed to compositions and methods targeting cells in a subject harboring conditions or at risk for conditions that would benefit from gas-based diagnostic and therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent, including gaseous substances, delivered in combination with the fluorochemical composition.

Compositions Containing Verteporfin, Ribavirin, Gemcitabine, Or Combinations Thereof And Methods Of Use For Treating Covid-19, Cancer, Or Non Cancer Diseases

View page
US Patent:
20230018580, Jan 19, 2023
Filed:
Sep 19, 2022
Appl. No.:
17/947711
Inventors:
Matthew McLeay - Omaha NE, US
International Classification:
A61K 9/00
A61K 45/06
A61K 47/26
A61P 31/14
A61K 31/7068
A61K 31/409
A61P 35/04
A61K 31/7056
A61K 31/02
A61K 31/728
A61K 31/197
A61K 31/198
Abstract:
Disclosed are pharmaceutical formulations and methods using Verteporfin Ribavirin and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).

Photodynamic Compositions And Methods Of Use

View page
US Patent:
20210299258, Sep 30, 2021
Filed:
May 7, 2019
Appl. No.:
17/054087
Inventors:
- San Diego CA, US
Matthew T. MCLEAY - Omaha NE, US
International Classification:
A61K 41/00
A61K 9/00
A61P 35/04
Abstract:
The present invention is directed to compositions and methods targeting cells in a subject harboring conditions or at risk for conditions that would benefit from gas-based diagnoses and therapies. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent, including gaseous substances, delivered in combination with the fluorochemical composition. The present invention also relates to the use of fluorochemical compositions in conjunction with oxygen and photo sensitizers to enhance photodynamic diagnosis and photodynamic therapy.

Compositions Containing Verteporfin, Ribavirin, Gemcitabine, Or Combinations Thereof And Methods Of Use For Treating Covid-19, Cancer, Or Non Cancer Diseases

View page
US Patent:
20210220265, Jul 22, 2021
Filed:
Jan 17, 2021
Appl. No.:
17/151191
Inventors:
Matthew McLeay - Omaha NE, US
International Classification:
A61K 9/00
A61K 45/06
A61K 47/26
A61K 31/7056
A61K 31/7068
A61K 31/409
A61P 35/04
A61P 31/14
Abstract:
Disclosed are pharmaceutical formulations and methods using Verteporfin Ribavirin and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).

Ribavirin Perflubron Emulsion Composition For Treating Viral Diseases

View page
US Patent:
20210069098, Mar 11, 2021
Filed:
Nov 17, 2020
Appl. No.:
16/950185
Inventors:
- SAN DIEGO CA, US
MATTHEW T. MCLEAY - OMAHA NE, US
International Classification:
A61K 9/00
A61K 31/198
A61K 45/06
A61K 31/351
A61K 31/7056
A61K 31/215
A61K 38/44
Abstract:
The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains “swine” 2009 HI N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg/ml) alone or combined with or without other antivirals, a perfluorocarbon emulsion and anti-inflammatory/anti-oxidants. Where applicable, the perfluorocarbon emulsion may dissolve these agents enabling a depot effect and possible protracted delivery. In addition, perfluorocarbon emulsions have the possible added benefit of oxygen carrying capacity and alveolar nitric oxide sequestration, which may reduce peroxynitrite formation and decrease Influenza severity.

Anti-Fibroblastic Fluorochemical Emulsion Therapies

View page
US Patent:
20200114006, Apr 16, 2020
Filed:
Dec 12, 2019
Appl. No.:
16/712150
Inventors:
Matthew T. McLeay - Omaha NE, US
International Classification:
A61K 47/06
A61K 47/46
A61K 45/06
A61K 33/00
A61K 9/12
A61K 9/107
A61K 31/00
A61K 9/00
Abstract:
The present invention is directed to compositions and methods targeting tissue resident cells, such as fibroblasts, in a subject harboring conditions or at risk for conditions that would benefit from anti-fibroblastic therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent delivered in combination with the fluorochemical composition.
Matthew Thomas Mcleay from Roeland Park, KS, age ~32 Get Report